FactorPad
Build a Better Process

Stock Risk Measures for Crispr Therapeutics Ag

A quantitative factor review as of September 30, 2021.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: October 05, 2021
See how we arrive at an overall risk score of 50 for CRSP below.

/ factorpad.com / stocks / f25gqj.html


An ad-free and cookie-free website.


CRSP Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Crispr Therapeutics Ag. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how CRSP stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Biological Product (except Diagnostic) Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f25gqj.html


CRSP stock risk
CRISPR THERAPEUTICS AG stock beta
CRSP risk report
CRSP f25gqj
CRSP risk analysis
CRSP volatility
CRISPR THERAPEUTICS AG credit risk
CRSP liquidity risk
CRSP leverage
CRSP valuation
CRSP systematic risk
CRSP specific risk
CRISPR THERAPEUTICS AG volatility
CRSP analysis
CRSP financial ratio

A newly-updated free resource. Connect and refer a friend today.